Summary:
A phase III multicenter, randomized, parallel group, controlled, double blind study to investigate the safety and efficacy of an investigational medication over 12 months in the treatment of bronchiectasis.
Qualified Participants Must:
• Have a confirmed diagnosis of (non-CF) bronchiectasis (diagnosed by CT, HRCT or bronchogram)
•
Be 18-80 years of age
•
Have FEV1 ≥40% and ≤ 80% predicted and ≥1L
•
Have a clinician documented history of at least 2 pulmonary exacerbations, each requiring antibiotic therapy, in the last 12 months prior to study entry and a total of at least 4 in the last 2 years prior to study entry
•
Have no actively treated or unstable nontuberculous mycobacterial (NTM) infection and not be under consideration for NTM treatment in the next 12 months
•
Have no unstable ABPA requiring steroid therapy (≤5mg dose oral steroids in stable ABPA accepted)
Qualified Participants May Receive:
All study related medication and healthcare at no cost. Eligible participants will be compensated for their time and travel.